AstraZeneca, headquartered at Cambridge Biomedical Campus, has announced a substantial £2 billion ($2.5 billion) investment to establish a new research and development (R&D) centre in Beijing.
This move comes shortly after the company cancelled a £450 million expansion of its vaccine manufacturing plant in Liverpool, raising questions about its commitment to UK-based projects. The company’s global headquarters and The Discovery Centre (DISC), its largest UK R&D facility, are located on the Cambridge Biomedical Campus, employing over 2,000 scientists. AstraZeneca also maintains over 130 active collaborations with the University of Cambridge.
The Beijing R&D centre will be AstraZeneca’s sixth globally and second in China, highlighting the significance of the Chinese market to the company’s growth strategy. Chief Executive Pascal Soriot emphasised the “extensive opportunities that exist for collaboration and access to talent” in China, reaffirming the company’s dedication to the region.
This investment coincides with AstraZeneca’s efforts to navigate ongoing investigations by Chinese authorities. Last year, the company’s China president, Leon Wang, was detained amid probes into alleged medical insurance fraud and illegal importation of unapproved medicines. Despite these challenges, AstraZeneca remains steadfast in its expansion plans within China.
The decision to invest heavily in China while retracting from the UK project has drawn criticism from some quarters. Sir Iain Duncan Smith, former Conservative leader, expressed concerns about collaborating with the Chinese regime, cautioning that AstraZeneca “will rue the day that they got into bed with this brutal dictatorial regime.”
As AstraZeneca deepens its ties with China, the company aims to bolster its global R&D capabilities, leveraging Beijing’s advancements in biology and artificial intelligence to accelerate the development of innovative medicines.
Leave a comment